VistaGen Therapeutics Q3 EPS $(0.22) Beats $(0.30) Estimate, Sales $411.40K Miss $544.50K Estimate
Author: Benzinga Newsdesk | February 13, 2024 05:31pm
VistaGen Therapeutics (NASDAQ:
VTGN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 84.51 percent increase over losses of $(1.42) per share from the same period last year. The company reported quarterly sales of $411.40 thousand which missed the analyst consensus estimate of $544.50 thousand by 24.44 percent. This is a 129.06 percent increase over sales of $179.60 thousand the same period last year.
Posted In: VTGN